The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

In Ensem's Phase I/II trial, the company is evaluating ETX-636 in more than 230 patients with solid tumors harboring a mutation in PIK3CA, the gene that encodes PI3Kα. In part A of the trial, ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

NEW YORK – The European Commission has granted conditional approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) for previously treated patients with unresectable, locally advanced or metastatic ...

NEW YORK – Neurogene this week said it has taken steps to begin a registrational trial to evaluate NGN-401, its investigational gene therapy for Rett syndrome, after reaching an agreement with the US ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

NEW YORK – Iksuda Therapeutics on Monday said it will expand an ongoing Phase I trial of the HER2-targeted antibody-drug conjugate (ADC) IKS014 in solid tumors to US sites. The Newcastle, ...